Compare Abeona Therapeutics Inc (ABEO) vs Domino's Pizza, Inc. (DPZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Domino's Pizza, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Domino's Pizza, Inc. trades at $305.31 (market cap $10.42B). The key difference: Domino's Pizza, Inc. is far larger — about 27.9× Abeona Therapeutics Inc's market cap, and Domino's Pizza, Inc. pays a 2.54% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DPZ | |
|---|---|---|
Market Cap | $373.32M | $10.42B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $485.53 |
52-Week Low | $4.17 | $282.89 |
Enterprise Value | $228.22M | $15.32B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Domino's Pizza (DPZ) trades at $313.14, up 0.47% on the day, but remains near its 52-week low amid a bearish technical trend. The company reported mixed Q1 2026 earnings with an EPS miss of $4.13 vs. $4.27 expected, though revenue growth has been steady, reaching $4.94B in 2025. Analyst consensus is bullish with a $386.07 price target, but recent CEO transition and slowing same-store sales present near-term headwinds. Cash flow from operations remains strong at $792M in 2025, supporting dividends and buybacks.
DPZ offers value with a P/E of 17.6x and solid profitability (net margin 11.9%), but high debt levels and competitive pressures pose risks. The stock's 25% YTD decline creates a potential entry point for long-term investors, though execution under new leadership and consumer spending trends will be critical for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →
